Allogene Therapeutics (NASDAQ:ALLO) Stock Rating Upgraded by JPMorgan Chase & Co.

Allogene Therapeutics (NASDAQ:ALLO) was upgraded by analysts at JPMorgan Chase & Co. from an “underweight” rating to a “neutral” rating in a research report issued to clients and investors on Thursday, MarketBeat.com reports.

A number of other equities analysts have also recently commented on the stock. Citigroup reissued an “outperform” rating on shares of Allogene Therapeutics in a research note on Tuesday. Jefferies Financial Group increased their price target on shares of Allogene Therapeutics from $6.00 to $10.00 and gave the company a “buy” rating in a report on Monday. Argus lifted their price target on Allogene Therapeutics from $1.60 to $3.85 and gave the stock a “market perform” rating in a research report on Tuesday. HC Wainwright boosted their price objective on Allogene Therapeutics from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Sanford C. Bernstein upped their price objective on Allogene Therapeutics from $1.60 to $3.85 and gave the company a “market perform” rating in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.44.

Allogene Therapeutics Stock Performance

NASDAQ ALLO opened at $2.17 on Thursday. The stock has a 50 day moving average price of $2.31 and a 200-day moving average price of $1.72. Allogene Therapeutics has a one year low of $0.86 and a one year high of $4.46. The company has a market capitalization of $529.00 million, a P/E ratio of -2.49 and a beta of 0.53.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.08. As a group, equities analysts predict that Allogene Therapeutics will post -1.28 EPS for the current fiscal year.

Insider Activity

In related news, CEO David D. Chang sold 95,269 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $1.80, for a total transaction of $171,484.20. Following the transaction, the chief executive officer directly owned 5,185,862 shares in the company, valued at approximately $9,334,551.60. This represents a 1.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Earl Martin Douglas sold 22,900 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $1.76, for a total transaction of $40,304.00. Following the completion of the sale, the senior vice president directly owned 564,948 shares in the company, valued at $994,308.48. This trade represents a 3.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 278,452 shares of company stock valued at $534,053 in the last quarter. 13.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Allogene Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Savant Capital LLC bought a new stake in shares of Allogene Therapeutics during the 3rd quarter worth approximately $27,000. Russell Investments Group Ltd. increased its stake in Allogene Therapeutics by 11,159.8% in the third quarter. Russell Investments Group Ltd. now owns 21,844 shares of the company’s stock worth $27,000 after purchasing an additional 21,650 shares during the period. Mercer Global Advisors Inc. ADV purchased a new stake in Allogene Therapeutics in the third quarter worth $30,000. Caitong International Asset Management Co. Ltd lifted its position in shares of Allogene Therapeutics by 5,267.6% during the third quarter. Caitong International Asset Management Co. Ltd now owns 24,047 shares of the company’s stock worth $30,000 after purchasing an additional 23,599 shares during the last quarter. Finally, Brighton Jones LLC lifted its position in shares of Allogene Therapeutics by 81.6% during the third quarter. Brighton Jones LLC now owns 25,168 shares of the company’s stock worth $31,000 after purchasing an additional 11,311 shares during the last quarter. 83.63% of the stock is currently owned by hedge funds and other institutional investors.

Key Allogene Therapeutics News

Here are the key news stories impacting Allogene Therapeutics this week:

• Positive Sentiment: HC Wainwright raised near‑term EPS forecasts across Q1–Q4 2026 and materially cut its FY2026 loss view (from ~($1.01) to ($0.66)), while maintaining a “Buy” rating and a $12 price target — a constructive analyst view that supports upside potential for the story and valuation.
• Positive Sentiment: Allogene published preclinical ALLO‑329 data in Nature Communications (supports the company’s autoimmune program and broader pipeline optionality). Allogene Announces Nature Communications Publication
• Positive Sentiment: Clinical readouts: ALPHA3 cema‑cel data showing strong MRD clearance and safety have been highlighted by coverage (supporting the therapeutic runway for first‑line LBCL). ALLO Rises on Strong MRD Clearance in ALPHA3
• Positive Sentiment: Multiple firms lifted price targets this week (Jefferies to $10, Baird to $9, Citizens to $8 and others), reflecting improving sell‑side sentiment and potential upside if clinical and financing risks ease.
• Neutral Sentiment: Options activity is mixed: there was an unusual spike in put volume (4,437 puts) and also reported large call activity on some days — signals of hedging and heightened trader interest but ambiguous directional intent.
• Negative Sentiment: Allogene priced a large public offering of 87.5 million shares at $2.00 per share to raise roughly $175M (underwriters have a 30‑day option for ~13.1M additional shares). The size and low price of the offering create meaningful near‑term dilution risk and are a primary near‑term negative driver for the stock. Allogene Announces Pricing of Public Offering
• Negative Sentiment: Market reaction: coverage noted a ~13% intra‑session slide tied to the equity raise and related dilution concerns — the financing appears to be the dominant reason for today’s weakness. Allogene Down After Equity Raise
• Negative Sentiment: Insider selling has been reported over the past six months (multiple sales by senior executives), which can heighten investor concern about share supply and executive conviction.

About Allogene Therapeutics

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.